Monisha Sebastin, MS, CGC, is Senior Genetic Counselor, Pediatrics at the Children's Hospital at Montefiore Einstein. In addition to providing genetic counseling services in genetics clinics, Ms. Sebastin specializes in rare diseases, cardiovascular genetics and immunogenetics.
After earning her Bachelor of Technology in genetic engineering at Sri Ramaswamy Memorial University in Chennai, India in 2014, Ms. Sebastin moved to New York to complete her Master of Science in human genetics at Sarah Lawrence College in 2018, where she studied genetic counseling. She later completed an online course in Genomic Annotation and Variant Interpretation with the Institute of Genomics and Integrative Biology in New Delhi, India in 2021.
Ms. Sebastin's research focuses on rare diseases, genetic counseling, cardiovascular genetics, immunogenetics and international and global genetic counseling. She has been principal investigator and contributor to several research projects, and her work has been published in numerous peer-reviewed journals. She has also given national and international presentations.
Ms. Sebastin is certified by the American Board of Genetic Counseling. She is the 2024 President of the New York State (NYS) Genetics Task Force and co-chairs the International Special Interest Group (ISIG) at the National Society of Genetic Counselors (NSGC). Her past leadership roles include serving as co-chair of the Pediatric and Clinical SIG, co-chair of the United States Special Interest sub-group of international SIG at NSGC and Chair of the education committee at the NYS Genetics Task Force. She is the 2022 Heart of Genetic Counseling Award recipient, nominated by a patient and presented by the National Society of Genetic Counselors (NSGC) and Invitae for exceptional dedication to quality patient care and contributions to the field of genetic counseling. Ms. Sebastin is trilingual - English (fluent), Tamil (fluent) and Hindi (conversational). She is a member of the National Society of Genetic Counselors, the New York State Genetics Task Force and the National Organization for Rare Disease (NORD).